Information on milk transferability of drugs is important for patients who wish to breastfeed. The purpose of this study is to develop a prediction model for milk-to-plasma...

DILIsym® X Product Brochure
DILIsym is Quantitative Systems Toxicology (QST) software capable of predicting and explaining Drug-Induced Liver Injury (DILI).

Quickening the Pace of Drug Discovery with AI
“The integration of our industry-leading ADMET Predictor and GastroPlus® mechanistic PBPK simulations into the initial generative chemical design process is what sets us apart from other machine learning drug design companies,” says AIDD Principal Scientist and former City of Hope Professor Jeremy Jones. “Our platform offers everything a medicinal chemist would want, at incredible speed.”

Lowly-buffered biorelevant dissolution testing is not necessarily biopredictive of human bioequivalence study outcome: Relationship between dissolution and pharmacokinetics
It has been revealed that buffer capacity of aspirated human intraluminal fluid is much lower than that of in vitro compendial dissolution media. Since buffer capacity signif

Consult + Coach
Accelerate Your Program and Invest in Your Future

Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition
Inhibition of the canalicular phospholipid floppase multidrug resistance protein 3 (MDR3) has been implicated in cholestatic drug-induced liver injury (DILI), which is clinically...

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
DSX is faster, more user-friendly, and scalable for high-performance computing

Plug n’ Play PBBM
The GastroPlus Plug n' Play PBBM Packages

Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
Initiates first steps in updated capital allocation strategy

What’s New in GastroPlus® v9.8.3?
Learn about the new and improved functionality to drive advances to PBBM/PBPK applications from discovery through post-approval.

GastroPlus® Additional Dosage Routes Brochure
Trust Our Gut... and Model Everywhere!

Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging
Basmisanil, is a lipophilic drug substance, exhibiting poor solubility and good permeability (BCS class 2). A validated physiologically based biopharmaceutics model (PBBM)...